← Oncology Approval Tracker

FDA DECISION ·

Jemperli + carboplatin + paclitaxel

dostarlimab-gxly + carboplatin + paclitaxel · GlaxoSmithKline

FDA approvalNew or expanded indicationEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For primary advanced or recurrent endometrial cancer with dMMR or MSI-H. Start with carboplatin and paclitaxel plus dostarlimab, then continue dostarlimab alone.

LAMPGEN ANALYSIS

Why it matters

This added immunotherapy to chemotherapy for a biomarker-selected advanced or recurrent population.

What research teams should watch

Document mismatch repair or MSI testing and the transition from combination to maintenance therapy.

PRIMARY RECORDS

Sources